CALR and neoplasm: Studies show that chemotherapy with doxorubicin (DOX) or oxaliplatin (OXA) can trigger an immune response via ICD of tumor cells 22,80, which increases the surface expression of pro-apoptotic calreticulin (CRT), promotes the maturation of antigen-presenting cells (APCs) and increases accumulation of CTLs in the tumors 81,82.